免疫化疗时代，IRF/MUM1表达>25%是弥漫性大B细胞淋巴瘤三年生存率的预测指标。

Expression IRF/MUM1>25% Predictor to Three-year Survival of Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era.

作者信息

Sofo-Hafizovic Alma, Chikha Adisa, Gojak Refet, Hadzimesic Emina Suljovic

机构信息

Hematology Clinic of the Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina.

Patology Institute of the Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina.

出版信息

Med Arch. 2016 Oct;70(5):342-347. doi: 10.5455/medarh.2016.70.342-347. Epub 2016 Oct 25.

DOI:10.5455/medarh.2016.70.342-347

PMID:27994293

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5136440/

Abstract

INTRODUCTION

Non Hodgkin lymphoma-Diffuse large B cell lymphoma (DLBC) is composed of more varieties of one disease. Analysis and understanding of a wide range of characteristics of the disease, which include: clinical, immunohistochemical, cytogenetic and molecular characteristics may improve treatment results.

AIM

achieving the estimated three-year survival and influence of IRF/MUM1 expression to three-year survival.

MATERIAL AND METHODS

A study was retrospective-prospective, patients were followed for seven years a period of dine. The study included 60 patients de novo DLBCL. Age was 18-72 years old, the average age 45 years, male 31 (51,7%) and female 29 (48.3%). Median follow-up was 47 months (3-91 months). To determine differentiation immunophenotype antibodies those were used anti-CD20, anti-CD10, anti-Bcl-6, IRF-4/MUM1, CD 138.

RESULTS

Included the GCB type was 65%. Impact prognostic index IPI>2 GBC vs non GBC p=0,038 X. Statistically significant difference was confirmed compared to the IPI> 2 to 3 year OS p<0,0005 X. Significantly longer three-year survival was provided in the group GCB 36 (92,3%) vs. non GCB 8 (38,1%) p=0,003 X. Clinical and immunohistochemical factors showed a significant impact to three-year survival by univariate: LDH p=0,005, MUM1 p=0,003, while CD10 p=0,069 was confirmed on the level of borderline impact. Using multivariate analysis, expression MUM1 has the greatest impact p<0.0005 OR=0.083 (95% CI 0.23-0.303) on the disease outcome - three-year survival.

CONCLUSION

expression MUM1 >25% has the greatest impact on the disease outcome - three-year survival.

摘要

引言

非霍奇金淋巴瘤 - 弥漫性大B细胞淋巴瘤（DLBC）是一种包含多种亚型的疾病。分析和了解该疾病的广泛特征，包括临床、免疫组化、细胞遗传学和分子特征，可能会改善治疗效果。

目的

实现估计的三年生存率以及IRF/MUM1表达对三年生存率的影响。

材料与方法

本研究采用回顾性 - 前瞻性研究方法，对患者进行了为期七年的随访。该研究纳入了60例初治弥漫性大B细胞淋巴瘤患者。年龄在18 - 72岁之间，平均年龄45岁，男性31例（51.7%），女性29例（48.3%）。中位随访时间为47个月（3 - 91个月）。为确定分化免疫表型，使用了抗CD20、抗CD10、抗Bcl - 6、IRF - 4/MUM1、CD138等抗体。

结果

生发中心B细胞（GCB）型占65%。国际预后指数（IPI）>2的GCB组与非GCB组相比，p = 0.038。与IPI>2相比，3年总生存率（OS）有统计学显著差异，p<0.0005。GCB组三年生存率显著更长，为36例（92.3%），而非GCB组为8例（38.1%），p = 0.003。临床和免疫组化因素在单因素分析中显示对三年生存率有显著影响：乳酸脱氢酶（LDH）p = 0.005，MUM1 p = 0.003，而CD10在临界影响水平上得到证实，p = 0.069。使用多因素分析，MUM1表达对疾病结局 - 三年生存率影响最大，p<0.0005，比值比（OR）= 0.083（95%可信区间0.23 - 0.303）。